Biofrontera Inc. (BFRI)
NASDAQ: BFRI · Real-Time Price · USD
0.9700
+0.0512 (5.57%)
At close: Oct 9, 2026, 4:00 PM EDT
0.9429
-0.0271 (-2.79%)
After-hours: Oct 9, 2026, 6:06 PM EDT
Biofrontera Employees
As of December 31, 2025, Biofrontera had 94 total employees, including 84 full-time and 10 part-time employees. The number of employees increased by 1 or 1.08% compared to the previous year. That makes Biofrontera the 31,780th largest employer in the world and 4,097th in the United States.
Employees
94
Change (1Y)
1
Growth (1Y)
1.08%
Revenue / Employee
$491,223
Profits / Employee
-$67,713
Market Cap
14.41M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 94 | 1 | 1.08% | 84 | 10 |
| Dec 31, 2024 | 93 | 8 | 9.41% | 92 | 1 |
| Dec 31, 2023 | 85 | 4 | 4.94% | 83 | 2 |
| Dec 31, 2022 | 81 | 12 | 17.39% | 81 | 0 |
| Dec 31, 2021 | 69 | 13 | 23.21% | 69 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Universe Pharmaceuticals INC | 216 |
| Rockwell Medical | 157 |
| Aytu BioPharma | 76 |
| Sonoma Pharmaceuticals | 10 |
| Gelteq | 8 |
| InMed Pharmaceuticals | 6 |
| Caring Brands | 3 |
| Shuttle Pharmaceuticals Holdings | 2 |
BFRI News
- 3 days ago - Biofrontera submits sNDA to FDA to expand Ameluz indication - TheFly
- 3 days ago - Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body - GlobeNewsWire
- 27 days ago - Biofrontera announces FDA approval of Ameluz supplemental new drug application - TheFly
- 27 days ago - Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma - GlobeNewsWire
- 4 weeks ago - FDA approves label update for Biofrontera’s Ameluz Gel - TheFly
- 1 month ago - Biofrontera Earnings Call Transcript: Q2 2026 - Transcripts
- 1 month ago - Biofrontera Earnings release: Q2 2026 - Filings
- 1 month ago - Biofrontera Quarterly report: Q2 2026 - Filings